The second issue concerns the unbalanced intellectual property provisions (TRIPs) of the Uruguay Round of trade talks, dictated by America's pharmaceutical and entertainment industries. These provisions restricted countries from making generic imitations of drugs, making many critically important medicines unaffordable in developing countries.